Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Blinded Two-Year Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Study

被引：0
|
作者：
Weinblatt, Michael [1 ]
Schiff, Michael [2 ]
Valente, Robert [3 ]
van der Heijde, Desiree [4 ]
Citera, Gustavo [5 ]
Elegbe, Ayanbola [6 ]
Maldonado, Michael [6 ]
Fleischmann, Roy [7 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Arthrit Ctr Nebraska, Lincoln, NE USA
[4] Leiden Univ, Med Ctr, Leiden, Netherlands
[5] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
JOURNAL OF RHEUMATOLOGY | 2014年 / 41卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
62
引用
收藏
页码：1476 / 1476
页数：1
相关论文
共 39 条
  • [31] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor study
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip
    Bessette, Louis
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1042 - 1042
  • [32] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Chaudhury, Sukanya
    Gellett, Amanda M.
    Hojnik, Maja
    Leage, Soyi Liu
    Li, Lingnan
    Mease, Philip
    Nash, Peter
    Pillai, Sreekumar G.
    Schulze-Koops, Hendrik
    Smolen, Josef
    Tahir, Hasan
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 125 - 125
  • [33] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [34] Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
    Smith, Tim
    Harnett, James
    Gruben, David
    Chen, Connie
    Agarwal, Ekta
    Woolcott, John
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [35] SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
    Mcinnes, I.
    Behrens, F.
    Mease, P. J.
    Kavanaugh, A.
    Ritchlin, C. T.
    Nash, P.
    Gratacos-Masmitja, J.
    Goupille, P.
    Korotaeva, T.
    Gottlieb, A. B.
    Martin, R.
    Ding, K.
    Pellet, P.
    Mpofu, S.
    Pricop, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 142 - 143
  • [36] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
    Smolen, J. S.
    Burmester, G-R
    Combe, B.
    [J]. LANCET, 2016, 388 (10061): : 2742 - 2742
  • [37] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
    Smolen, J. S.
    Burmester, G-R
    Combeet, B.
    [J]. LANCET, 2017, 389 (10068): : E2 - E2
  • [38] MULTICENTRE, RANDOMISED, OPEN-LABEL, ASSESSOR-BLINDED, PARALLEL-GROUP HEAD-TO-HEAD COMPARISON OF THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS NAIVE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: 24-WEEK RESULTS
    Mease, Philip J.
    Smolen, Josef S.
    Behrens, Frank
    Nash, Peter
    Leage, Soyi Liu
    Li Lingnan
    Tahir, Hasan
    Gooderham, Melinda
    Krishnan, Eswar
    Emery, Paul
    Pillai, Sreekumar
    Helliwell, Philip
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 261 - 262
  • [39] HEAD-TO-HEAD STUDY EVALUATING THE COMBINED ACR50/PASI100 TREATMENT RESPONSE OF IXEKIZUMAB VERSUS ADALIMUMAB: INDIVIDUAL PATIENT DATA FROM A RANDOMIZED, OPEN-LABEL STUDY IN BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS THROUGH WEEK 52
    Kavanaugh, A.
    Lubrano, E.
    Muram, T.
    Lin, C. Y.
    Leage, S. Liu
    Van den Bosch, F.
    Kristensen, L. E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 763 - 763
1234